In this video, health-care analyst David Williamson discusses the sector's three biggest losers today, including VIVUS after posting poor third-quarter results. Watch and find out what investors should take away from these disappointing results and catch up on the day's other big movers.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Qsymia's launch disappoints the market.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson and The Motley Fool own shares of Dendreon. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Arena Pharmaceuticals
ARNA
VIVUS
VVUS
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
1 Undervalued Growth Stock That Could Go Parabolic Soon
Why Scholar Rock Shares Are Soaring Today
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.